Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients
about
Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysisA critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinomaPredictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agentsFine tuning chemotherapy to match BRCA1 statusBRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancerTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerDNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cellsRobust selection of cancer survival signatures from high-throughput genomic data using two-fold subsamplingCustomized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell linesERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancerPredictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposideGene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.How close are we to customizing chemotherapy in early non-small cell lung cancer?Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?Against Lung Cancer Cells: To Be, or Not to Be, That Is the ProblemSynthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.Personalized therapy for urothelial cancer: review of the clinical evidence.Independent and functional validation of a multi-tumour-type proliferation signature.Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerIndividualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1RRM1 *151A>T, RRM1 -756T>C, and RRM1 -585T>Gis associated with increased susceptibility of lung cancer in Chinese patients.Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments.Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum.Emerging treatment options in the management of non-small cell lung cancer.Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.Role of genotyping in non-small cell lung cancer treatment: current status.The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.Molecular biomarkers for predicting chemotherapy response in lung cancer.Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.Customizing chemotherapy in non-small cell lung cancer: the promise is still unmet.Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
P2860
Q21198839-50FBE32E-CFF0-46DA-AF11-3155D70CB453Q21558626-E25C6566-1DBA-4474-9204-71C21B3544F1Q26748931-994F8049-202C-452F-87DA-937D8A7C7C1FQ27694529-9AC99DDD-DC07-4278-9017-AAFE0B0F7A7BQ27851697-49F5748A-7422-4858-B06E-DE6AE4C76CCEQ28246258-EC9B9C27-178B-423B-9518-BD2F3B93C9E7Q28396304-EE8CDCC7-ADB5-4AD0-B84E-961C7E3A31B3Q28481440-37924928-C6B3-4756-8311-AF3E49323122Q30858189-EA5B8647-07CA-456B-B77B-D5EBD1ECF5CDQ33438894-0BAEF81D-9447-4300-B180-9D3002FCD76FQ33538053-E6EDB611-F161-445A-9FD1-13123DC4D411Q33582958-2190AACD-5D99-4080-9D06-090F558F8CB1Q33722508-2AACF6A4-E397-403C-A4BE-4CAD2A071A9EQ33793009-0A768E12-913D-48BD-9205-7884F6D73C26Q34543746-FB53ED30-5D5C-4F29-9180-57CF06197A32Q34994818-167B94E8-56ED-4627-B846-BBB76C413202Q35038441-5A3B9FE1-5105-4788-A90F-FD7A20FF89EAQ35146944-13428AC7-4297-4EAA-A1AD-A31FDC532EECQ35200402-957E0D17-2C11-408B-A358-D8AAFF0E054DQ35623645-854B5D10-034C-4F5D-99EF-B968706E35C1Q35909171-2A59D923-8C85-4110-9A92-99ED0E01053AQ36062762-27E738A7-3B37-4CD2-B967-22D33B619A5EQ36117179-0B0980F3-57AA-4AE6-9120-22594D5835B7Q36333164-673798B4-80FE-4E0B-BF12-4080C0D1E3D4Q36350128-6624F125-B615-4248-A1C3-70669D5432EEQ36563172-70815FB8-8735-447E-8EB9-FEE0428D066DQ37148971-2D193613-F6D4-49DB-BA61-B53FCC9A7497Q37353925-87AB2F4D-B578-487D-8FF6-B6E51FFF63E5Q37483162-48F6A32C-3DE0-4B1C-9DB3-EC077EA5B2DFQ37581936-5E3D69A7-8D35-4378-B428-A79A352870FEQ37645201-D7427FA4-EB2E-44DF-B869-C5F17D4A1442Q37756959-B2B6376E-2786-4673-9F60-40F5E380540FQ37871213-B80DF038-CCA1-42F3-8EE4-F3DB03F50549Q37956397-D6E9FAD3-660D-4273-8AAE-F1B3CCD4F24CQ37983690-D4BE0BF5-2EBB-4681-95DF-2473CFE3397DQ38089839-D7F5BD51-DA2B-45DC-B75E-0C399FCA5F86Q38203468-B20487FE-8186-4DBD-BC34-F101777906C5Q38923059-AEAE5537-F473-4FF3-A274-A7CB590DA79FQ38936288-D583AA23-1C87-4FD3-8A5D-8DFCAF65BAF6Q39095223-C82C7AE3-6E23-4B6E-99A4-40BE9B9D53E7
P2860
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@ast
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@en
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@en-gb
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@nl
type
label
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@ast
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@en
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@en-gb
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@nl
altLabel
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-Cell Lung Cancer Patients
@en
prefLabel
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@ast
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@en
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@en-gb
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@nl
P2093
P2860
P3181
P1433
P1476
Tumor BRCA1, RRM1 and RRM2 mRN ...... mall-cell lung cancer patients
@en
P2093
Chara Papadaki
Dimitris Mavroudis
Eustathios Staphopoulos
Ioannis Boukovinas
John Souglakos
Jose Javier Sanchez
Maria Sanchez-Ronco
Maria Trypaki
Miquel Taron
Pedro Mendez
P2860
P3181
P356
10.1371/JOURNAL.PONE.0003695
P407
P577
2008-01-01T00:00:00Z